PTC Therapeutics
PTCT
PTCT
166 hedge funds and large institutions have $1.45B invested in PTC Therapeutics in 2018 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 57 increasing their positions, 42 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
166
Holders Change
+18
Holders Change %
+12.16%
% of All Funds
3.81%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.14%
New
46
Increased
57
Reduced
42
Closed
26
Calls
$24.9M
Puts
$23.9M
Net Calls
+$970K
Net Calls Change
+$3.78M
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$77.4M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$35.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.5M |
| 4 |
Goldman Sachs
New York
|
+$19.1M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$16M |
Top Sellers
| 1 |
SCM
Scopia Capital Management
New York
|
-$122M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$23.6M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$19.7M |
| 4 |
Citigroup
New York
|
-$15.9M |
| 5 |
Two Sigma Investments
New York
|
-$14M |
